Diabetes therapy : research, treatment and education of diabetes and related disorders|2025|Fadini G|1 citation
PMID: 40526203
A dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and obesity.
BACKGROUND: Dual and triple incretin-based agonists, targeting combinations of GLP-1, GIP, and glucagon receptors, represent an innovative approach in T2DM care. However, comparative efficacy and safety analyses tailored to receptor-specific strategi…
RATIONALE: Managing type 2 diabetes mellitus (T2DM) in adults with severe obesity frequently coexists with obstructive sleep apnea (OSA), complicating metabolic control and quality of life. Real-world, objective monitoring-documented trajectories thr…
INTRODUCTION: Tirzepatide is a new molecule capable of controlling blood glucose levels by combining the dual agonism of glucose-dependent insulinotropic polypeptide (GIP) and glucose-like peptide-1 (GLP-1) receptors. The Food and Drug Administration…
BACKGROUND: Tirzepatide reduced weight and improved cardiometabolic risk factors for participants in the SURMOUNT-1 trial. The changes in cardiometabolic risk factors by degree of tirzepatide-induced weight reduction across a wide spectrum of weight…
Tirzepatide, a dual agonist of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, is recognized for its effectiveness in regulating glucose levels and promoting weight loss. This systematic review aims to evaluate…
BACKGROUND: Overweight and obesity pose serious health challenges for individuals and societies. This study aims to facilitate personalised treatment of obesity by summarising recent research on weight-loss pharmacotherapies, with a focus on their ef…
BACKGROUND: Tirzepatide (TZP) has demonstrated efficacy for glycemic control and weight loss in subjects with type 2 diabetes (T2D). However, previous clinical trials were not conducted under the treatment of glucagon-like peptide-1 receptor agonists…
OBJECTIVE: Glucagon-like peptide 1 receptor agonists (GLP-1RAs) are approved for weight loss, diabetes, and cardiovascular risk reduction. Despite widespread use, GLP-1RAs have not been well studied in patients with rheumatoid arthritis (RA). We exam…
INTRODUCTION: Persistent genital arousal disorder/genitopelvic dysesthesia (PGAD/GPD) is associated with poor quality of life. Due to social stigma and its heterogeneous nature, many patients suffer without treatment. AIMS: This case presents the fir…
BACKGROUND: Obesity poses a significant public health and economic challenge in the United States (U.S.), with rising prevalence, particularly among individuals enrolled in Medicaid-the nation's public health insurance program for low-income populati…
The rate of weight reduction during obesity treatment declines over time and eventually reaches a weight plateau. We investigated factors associated with time to weight plateau (TTWP) in tirzepatide-treated participants with obesity or overweight in…
Obesity is associated with an increased cardiovascular risk. Drugs with glucagon-like peptide-1 receptor agonist (arGLP-1) action for overweight/obesity, such as liraglutide, semaglutide, and tirzepatide, have shown improvements in weight and body co…
The rise of compounded weight-loss drugs has emerged as a pressing global health issue, threatening consumers and health-care systems. Factors fueling this crisis include the desire for rapid weight-loss options, inadequate regulatory frameworks, and…
INTRODUCTION: GLP-1 receptor agonists (GLP1-RAs) are increasingly prescribed as an alternative to bariatric surgery for weight loss, and may pose as an alternative to conversion Roux-En-Y Gastric Bypass (cRYGB) in patients with insufficient weight lo…
PURPOSE OF REVIEW: Heart failure with preserved ejection fraction (HFpEF) is increasingly prevalent among individuals with obesity, primarily due to metabolic dysfunction and structural cardiac remodeling. This review explores the emerging therapeuti…